Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Results 121-140 of 515

Ref Title
TA173 Hepatitis B - tenofovir disoproxil fumarate: costing statement
TA172 Head and neck cancer (squamous cell carcinoma) - cetuximab: costing template
TA171 Multiple myeloma - costing statement
TA170 Venous thromboembolism - rivaroxaban: costing statement
TA169 Renal cell carcinoma - sunitinib: costing template
TA168 Influenza - zanamivir, amantadine and oseltamivir (review): costing statement
TA167 Abdominal aortic aneurysm - endovascular stent-grafts: costing statement
TA166 Hearing impairment - cochlear implants: costing tool
TA165 Organ preservation (renal) - machine perfusion and static storage: costing statement
TA164 Hyperuricaemia - febuxostat: costing template
TA163 Ulcerative colitis (acute exacerbations) - infliximab: costing statement
TA162 Lung cancer (non-small-cell) - erlotinib: costing statement
TA161 Osteoporosis - secondary prevention including strontium ranelate: costing template
TA160 Osteoporosis - primary prevention: costing template
TA159 Pain (chronic neuropathic or ischaemic) - spinal cord stimulation: costing template
TA158 Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: cost template
TA157 Venous thromboembolism - dabigatran: costing statement
TA156 Routine antenatal anti-D prophylaxis for women who are rhesus D negative (review): costing statement
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib: cost template
TA154 Hepatitis B - telbivudine: costing statement

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.